Hancock, MD, July 25, 2016 (GLOBE NEWSWIRE) — PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the “Company”), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, is pleased to announce the additions of Dr. Joel Beth Mitchel-Navratik, Vice President of Veterinary Affairs, and Dr. Vivek Ramana, Chief Medical Officer, to the management team.
Dr. Joel Beth Mitchel-Navratik Vice President of Veterinary Affairs
Dr. Mitchell-Navratik holds a Bachelor of Science Degree in Zoology and a Doctorate in Veterinary Medicine from the University of Florida. After university, she undertook an internship in Small Animal Medicine and Surgery at The Animal Medical Center and Bobst Hospital in New York City in 1994. Those same years, she joined the Aventura Animal Hospital and was soon promoted to the position of Chief of Staff within the facility. This is a position she has held since then. One of her biggest achievements at the facility has been to expand Aventura Animal Hospital to a full service hospital with an emergency care unit that is open 24 hours a day, 7 days a week.
Since 2001, Dr. Joel Beth Mitchell Navratik has served as the Corporate Medical Director for Pet Medical Centers, LLC. in South Florida. Pet Medical Centers is comprised of 8 state of the art small animal veterinary hospitals employing 27 veterinarians and 162 staff members. Pet Medical Centers offers a comprehensive approach to Veterinary Care, which includes internal medicine, surgery, radiology, ultrasound, CT imaging, boarding, grooming, preventive medicine and a fully stocked pharmacy. Pet Medical Centers is the largest privately held group of veterinary hospitals in the Unites States.
Dr. Mitchel-Navratik has used Escozine for Pets in her clinical practice and has observed its therapeutic benefit firsthand.
Dr. Mitchel-Navratik will be responsible for liaison with the professional veterinary community and will lead the clinical portion of our upcoming FDA trials.
“Veterinary Medicine is in need of an alternative all natural affordable oncologic (cancer) treatment that is safe for our pets. The Escozine for Pets FDA trials will soon be starting, providing the data we need to support our anecdotal trials that we have seen success with so far. I look forward to sharing the results with the pet world.” stated Dr. Mitchel-Navratik
Dr. Vivek Ramana Chief Medical Officer
Dr. Ramana received his medical degree from the University of Belgrade, Serbia and specialized in Radiation Oncology and Clinical Pathology. He did his Post Graduate studies in Molecular Immunology, Genetics and Molecular Biology at the University of New Haven, CT and Post-Doctoral Studies in Clinical Pharmacology, Drug Research & Development and Regulation at TUFTS University in Boston. Dr. Ramana is currently a principal of InnoVision Therapeutics.
Dr. Ramana has extensive experience in bringing drugs through the FDA approval process and has over four years experience working with Escozine in the laboratory and clinical setting.
Dr. Ramana will be responsible for building and maintaining our portfolio of scientific studies supporting the safety and efficacy of Escozine for Pets. PetLife will have a Pre-INAD meeting with CVM and subsequently conduct the require studies per FDA guidance. He will oversee the safety, toxicology, and clinical studies portions of our upcoming FDA trial and be our direct liaison with the FDA throughout this process.
Dr. Salvagno, Chairman and CEO of PetLife, stated “I am proud to announce that PetLife Pharmaceuticals has engaged Drs. Vivek Ramana and Joel Beth Mitchel-Navratik to be part of our team. These two professionals have significant experience with Escozine for Pets and bring their respective clinical and laboratory expertise in support of our efforts to end suffering in our Companion Animals. Their hands on experience with the drug and Dr. Ramana’s many years of experience in working with the FDA with numerous successful projects will help the company in meeting the estimated time lines and budget anticipated to complete the FDA studies.”
About PetLife Pharmaceuticals, Inc.
PetLife Pharmaceuticals (OTCQB: PTLF) (http://www.PetLifePharma.com) is a registered US Veterinary Pharmaceutical company, incorporated in 2012.
PetLife has developed and is launching a new generation of high potency veterinary cancer medications and nutraceuticals for companion pets — Escozine for Pets™. It is based on the same patented ‘Escozine for Humans’ formula that has been sold by affiliated companies worldwide in 40 countries. Escozine for Pets™ uses a patented polarization technology that potentiates the main ingredients to dramatically increase their effectiveness.
PetLife’s mission is to bring its new, scientifically proven, non-toxic, potentiated bioactive nutraceuticals and prescription medication to the world of veterinary oncology — with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. In the US alone, consumer spending on domestic companion animals reached over $60 billion in 2015 with over $29 billion spent on veterinary care and medications.
Safe Harbor
Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: PetLife encourages those interested in our Company to rely only on information included in our filings with the United States Securities and Exchange Commission which can be found at www.sec.gov. Statements released by the Company, that are not purely historical are forward-looking within the meaning of the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the company’s expectations, hopes, intentions, and strategies for the future. Investors are cautioned that forward-looking statements involve risk and uncertainties that may affect the Company’s business prospects and performance. The Company’s actual results could differ materially from those in such forward-looking statements. Risk factors include but are not limited to general economic, competitive, governmental, and technological factors as discussed in the Company’s filings with the SEC on Forms 10-K, 10-Q, and 8-K. The Company does not undertake any responsibility to update the forward-looking statements contained in this release.
CONTACT: Investor Relations: Invicto Group info@invictogroup.com 800-928-7462 Ext. 801
